ABSTRACT
INTRODUCTION
Bicoid-interacting protein 3 (BCDIN3) was initially isolated as a protein that interacts with the homeodomaincontaining transcription factor, Bicoid, in Drosophila (1, 2) . BCDIN3 contains an S-(5 -adenosyl)-L-methionine (AdoMet) binding motif, and is homologous to a conserved family of eukaryotic protein methyltransferases acting on RNA-binding proteins (2, 3) . BCDIN3 is required for embryonic development in Drosophila (4) . Subsequent studies revealed that the human BCDIN3 homolog monomethylates the 5 -␥ -phosphate of 7SK RNA, a non-coding RNA involved in regulating the activity of the positiveacting transcription elongation factor, P-TEFb, a cyclindependent kinase complex (5, 6) . Monomethylation of the 5 -␥ -phosphate of 7SK RNA protects 7SK from degradation and controls the activity of P-TEFb; therefore, BCDIN3 was renamed methylphosphate capping enzyme, MePCE (7, 8) .
The BCDIN3 Domain containing protein, BCDIN3D, is conserved from worm to human (9) . The biological properties and function of BCDIN3D have not been characterized. BCDIN3D mRNA is overexpressed in human breast cancer cells, and the elevated expression of BCDIN3D is related to poor prognosis in breast cancer (10, 11) . Recently, it was reported that BCDIN3D dimethylates the 5 -monophosphate of specific precursor miRNAs (premiRNAs), such as the tumor suppressor miR145 (12) (13) (14) , in MCF-7 breast cancer cells (9) . Dimethylation of the 5 -monophosphate of the pre-miRNA negatively regulates the subsequent processing by Dicer in vitro (9, 15) , and results in the downregulated expression of the mature miRNA form. The shRNA-mediated depletion of BCDIN3D also reportedly results in the suppression of the tumorigenic phenotype of MDA-MB-231 breast cancer cells. Thus, BCDIN3D was proposed to promote the cellular invasion of breast cancer cells, by downregulating the expression of tumor suppressor miRNAs through the dimethylation of the 5 -monophosphate of the corresponding pre-miRNAs (9) .
The mechanisms by which BCDIN3D recognizes specific pre-miRNAs and negatively regulates the expression of matured miRNAs in breast cancer cells are not well understood. To identify other possible target RNAs that are methylated by BCDIN3D, and to clarify the mechanism by which BCDIN3D recognizes specific RNAs, we analyzed the BCDIN3D-binding RNAs in human HEK293T cells.
Here, we report that cytoplasmic histidyl tRNA (tRNA His ) is the primary target of BCDIN3D in HEK293T cells. We show that cytoplasmic tRHA His tightly binds to BCDIN3D in vivo, and the 5 -monophosphate of cytoplasmic tRNA
His is monomethylated by BCDIN3D in vitro and in vivo. BCDIN3D monomethylates tRNA His more efficiently than pre-miR145 by over two orders of magnitude in vitro, and never dimethylates the 5 -monophosphates of tRNA
His and pre-miR145. BCDIN3D recognizes the unique structures within cytoplasmic tRNA His --the additional guanosine residue at position −1 (G −1 ) and the eight-nucleotide acceptor helix with the G −1 -A 73 mispair, which are exceptional features among cytoplasmic tRNA species. The monomethylation of the 5 -phosphate of cytoplasmic tRNA His protects it from degradation in vitro. Therefore, BCDIN3D acts as a cytoplasmic tRNA His -specific 5 -methylphosphate capping enzyme. The involvement of the 5 -monophosphate methylation of cytoplasmic tRNA His and/or tRNA His itself in the tumorigenic phenotype of breast cancer cells is discussed.
MATERIALS AND METHODS

BCDINS3D-expressing stable cell lines
HEK293T and Flp-In TM T-REx TM -293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% FBS, under a humidified 5% CO 2 atmosphere at 37
• C. The stable human cell line expressing streptavidin binding protein (SBP)-fused BCDIN3D (SBP-BCDIN3D) was established by Flp Recombinase-Mediated Integration (Flp-In system, Invitrogen, Japan), according to the manufacturer's instructions. The synthetic cDNA encoding human BCDIN3D was purchased from Eurofin Genomics, Japan, and was cloned into the pcDNA5/FRT/TOFlag-HA-SBP vector (kind gift from Dr. Yamashita at Yokohama City University, Medical School). The resultant BCDIN3D expression plasmid, pcDNA5-SBP-BCDIN3D, was transfected into the host Flp-In TM T-REx TM -293 cells, using Lipofectamine 2000 (Invitrogen, Japan). The cell line harboring pcDNA5-SBP-BCDIN3D was selected with hygromycin (100 g/ml) and blasticidin (10 g/ml) for two weeks, according to the manufacturer's instructions.
Preparation of SBP-BCDIN3D-associating RNAs
The stable cell lines expressing SBP-BCDIN3D were expanded to ten 10 cm plates, and SBP-BCDIN3D expression was induced by a treatment with 500 ng/ml of doxycycline for 48 h. The cell extracts were prepared with cell lysis buffer, containing 10 mM Tris-Cl, pH 8.0, 150 mM KCl, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 5 mM DTT, 0.5 mM PMSF and complete protease cocktail (Roche, Japan) (buffer-A). SBP-BCDIN3D was purified using streptavidin beads (GE Healthcare, Japan). The beads were washed with buffer-A, and SBP-BCDIN3D was eluted by buffer-A containing 2 mM biotin (Sigma-Aldrich, Japan). The SBP-BCDIN3D associating RNAs were prepared using ISOGEN II (Nippon Gene, Japan), and separated by 10% (w/v) polyacrylamide gel electrophoresis under denaturing conditions, and the gel was stained with SYBR-Gold Nucleic Acid Stain (Invitrogen, Japan).
Mass spectrometric analysis of RNAs
The gel-purified RNA was digested by RNases, and the resultant RNA fragments were analyzed by capillary LC-nano ESI-mass spectrometry, as described previously (16, 17) . The gel-purified RNA-x (0.1 g) was digested with RNase T 1 (Epicentre) or RNase A (Ambion) and analyzed by an LTQ Orbitrap mass spectrometer (ThermoFisher Scientific, Japan), with a nano-electrosprayer connected to a splitless nanoflow high pressure liquid chromatography system (DiNa, KYA Technologies).
Expression and purification of BCDIN3D in E. coli
The DNA encoding human BCDIN3D was cloned between the Nde I and Xho I sites of the pET15b vector (Novergen, Japan). Escherichia coli BL21(DE3) cells were transformed by the plasmid and grown in LB medium containing 50 g/ml ampicillin at 37
• C until the A 600 reached 0.8, and the expression of histidine-tagged BCDIN3D was induced by the addition of IPTG (isopropyl-␤-D thiogalactopyranoside) at a final concentration of 0.1 mM for 12 h at 20
• C. The cells were harvested, sonicated in buffer containing 50 mM Tris-Cl, pH 7.0, 500 mM NaCl, 5 mM ␤-mercaptoethanol, 10 mM imidazole and 10% (v/v) glycerol (buffer-B), and centrifuged at 100 000 g for 1 h at 4
• C. The clear supernatant was applied to a Ni 2+ -NTA agarose column (QIAGEN, Japan) equilibrated with buffer-B. The column was washed with buffer-B, and the protein was eluted with buffer containing 50 mM Tris-Cl, pH 7.0, 500 mM NaCl, 5 mM ␤-mercaptoethanol and 400 mM imidazole. The protein was further purified by chromatography on Hi-Trap Q and Hi-Trap Heparin columns (GE Healthcare, Japan). Finally, the protein was purified by chromatography on a Hi-Load 16/60 Superdex 200 column (GE Healthcare, Japan), in buffer containing 25 mM Tris-Cl, pH 7.0, 200 mM NaCl and 10 mM ␤-mercaptoethanol, concentrated to 3 mg/ml and stored at −80
• C. The catalytically inactive BCDIN3D protein with the D72A/G74A mutations was also prepared as described above.
In vitro methylation assay
In vitro methylation of RNAs was carried out by the trichloroacetic acid (TCA) precipitation of reaction products. For standard assays using 14 C-S-adenosylmethionine (AdoMet), a reaction mixture (80 l volume) containing 50 mM Tris-Cl, pH 7.9, 50 mM KCl, 5 mM MgCl 2 , 0.1 mM EDTA, 2 mM DTT, 5 % (v/v) glycerol, 2 M RNA, 50 M [ 14 C]-AdoMet (40 mCi/mmol, PerkinElmer, Japan), and 0.1 M BCDIN3D was incubated at 37
• C. An aliquot (10 l) was withdrawn at the indicated time from the reaction solution and spotted onto a Whatman 3MM filter (GE Healthcare, Japan) that was pre-soaked with cold 10% (w/v) TCA. After the filters were washed with cold 10% (w/v) TCA, they were washed with ethanol and dried.
Nucleic Acids Research, 2017, Vol. 45, No. 9 5425 The filters were suspended in Ultima Gold liquid scintillation cocktail (PerkinElmer, Japan) in vials, and the radioactivities on the filters were quantified with a liquid scintillation counter (Beckman Coulter). To visualize the 14 Cmethylated RNA products, after the reaction, the RNAs were purified by phenol-chloroform treatment, followed by ethanol precipitation, and separated by 10% (v/v) polyacrylamide gel electrophoresis under denaturing conditions. The gel was dried and exposed to an imaging plate for 16 h, and the intensities of the methylated RNAs were quantified with a BASS2000 imager (Fujifilm, Japan). For kinetic analysis, the specific activity of 3 H-AdoMet (55 Ci/mmol, PerkinElmer, Japan) was adjusted to 1.1 Ci/mol (500 M) with non-radiolabeled AdoMet (Sigma-Aldrich, Japan), and used for the assays. Reaction mixtures (10 l), containing 50 mM Tris-Cl, pH 7.9, 50 mM KCl, 5 mM
, and various concentrations of RNAs (0.125-15 M), were incubated at 37
• C for 10 min. RNA substrates (pre-miR145, tRNA His , tRNA Phe and their variants) were synthesized, using plasmids encoding the respective template DNA sequences downstream of the T7 promoter, by T7 RNA polymerase in the presence of excess GMP, and were purified by 10% (w/v) polyacrylamide gel electrophoresis under denaturing conditions. The RNA mini-helices corresponding to the top-half of cytoplasmic tRNA His , with 5 -monophosphate and its variants (Supplementary Table S1 ), were purchased from FASMAC, Japan.
Construction of BCDIN3D knockout cells by CRISPR/Cas9
BCDIN3D knockout cells were generated by the CRISPRCas9 system (18) . Oligonucleotides encoding sgRNAs (sgRNA1 or sgRNA2), which target exon 1 of the BCDIN3D gene, were cloned into the pX330 (Addgene plasmid 42230) vector (19) . The nucleotide sequences of the oligonucleotides encoding the sgRNAs are shown in Supplementary Table S1 . HEK293T cells were seeded into 24-well plates at a density of 250 000 cells per well, and were used for transfection. Cells were transfected with 300 ng of PX330 containing the sgRNA sequence, 100 ng of pLL3.7-puro and 100 ng of pEGFP-N1, using Lipofectamine 3000 (Life Technologies, Japan) according to the manufacturer's protocol. After 24 h, the transfection efficiency was estimated from the fraction of fluorescent cells, and transfected cells were selected by adding 5 g/ml of puromycin (Sigma Aldrich) for 5 days. After 5 days, the cells were diluted to obtain isolated clones. The isolated HEK293T cells were further transfected with PX330 containing the sgRNA sequence, to enhance the possibility of obtaining BCDIN3D knockout cells, and isolated clones were obtained as described above. The knockouts of the BCDIN3D gene were confirmed by DNA sequencing of PCR fragments spanning the target sites, and the lack of BCDIN3D expression in the isolated cells was confirmed by western blotting using an anti-BCDIN3D antibody (Sigma Aldrich). Cytoplasmic tRNA His species were isolated from total tRNA fractions, prepared from HEK293T and BCDIN3D knockout cells, by the solidphase hybridization method (20) (21) (22) . The 3 -biotinylated oligonucleotide probe, with the sequence complementary to the 3 -terminal 30 nucleotides of cytoplasmic tRNA His (5 -CCGTGACTCGGATTCGAACCGAGGTTGCTGbiotin-3 ), was purchased from Eurofins, Japan. The isolated tRNA His species were further purified by 10% (v/v) polyacrylamide gel electrophoresis under denaturing conditions.
Measurement of cell growth
For measurement of cell growth, HEK293T, KO1 and KO2 cells were seeded in a 96-well plate (2500 cells/ well; 100 l medium) and cultured at 37
• C. Cell proliferation was measured using a CellTiter-Blue Cell Viability Assay (Promega, Japan), according to the manufacturer's instructions. At the indicated times (1, 2, 3 and 4 days), the CellTiter-Blue Reagent (20 l/well) was added, and the cells were incubated for 1 h before recording the fluorescence (560Ex/590Em), using a GloMax Multi-Detection System (Promega, Japan).
In vitro aminoacylation assay
The tRNA
His transcript with the 5 -monophospate was methylated by BCDIN3D in vitro, and the resultant tRNA His with a 5 -monomethylphosphate was gel-purified. The fraction of methylated tRNA His (tRNA His pmG -1 ) was found to be more than 99%, as revealed by the LC-mass spectrometric analysis. The DNA encoding human histidine tRNA synthetase (HisRS) lacking the C-terminal three amino acids (C507I508C509) was cloned between the Nde I and Xho I sites of the pET15b vector (Novagen, Japan). The hexa-histidine-tagged HRS was expressed in Escherichia coli BL21(DE3) cells, and purified as described above. Reaction solutions containing 50 mM Tris-Cl, pH 7.6, 100 mM KCl, 10 mM MgCl 2 , 8 mM DTT, 2.5 mM ATP, 60 M L-[
14 C]-histidine (320 mCi/mmol, PerkinElmer, Japan), tRNA His variants (0-7.5 M) and 5 nM HisRS were incubated at 37
• C for 10 min. The reaction solutions were spotted onto Whatman 3MM filters (GE Healthcare, Japan) pre-soaked with cold 10% (w/v) TCA. The filters were washed with cold 10% (w/v) TCA, and then with ethanol and dried. The radioactivities on the filters were quantified as described above.
Northern blotting
Total RNAs or smaller RNAs (shorter than 200 nucleotides) from human cells were purified with the Isogen-II (Nippon Gene, Japan) or NucleoSpin miRNA (Takara, Japan) reagent, according to the manufacturer's protocol. The RNAs (2.5-10 g) were separated by 10% (v/v) polyacrylamide gel electrophoresis under denaturing conditions, and blotted onto a Hybond-N+ membrane (GE Healthcare, Japan) using a Trans-Blot SD semi-dry Electrophoretic Transfer Cell (Bio-Rad, Japan), according to the manufacturer's protocol. Hybridization was performed overnight at 55
• C in PerfectHyb Hybridization solution (Toyobo, Japan), using 5 -32 P-labeled oligo DNA probes. The membrane was washed three times in 2 × standard saline citrate (SSC) and 0.1% (w/v) SDS at 55
• C for 20 min. The DNA sequences used as specific probes are shown in Supplementary Table S1 .
Quantitative PCR
Smaller RNAs (shorter than 200 nucleotides) from human cells were purified, as described above. The expression level of mature miR145 relative to that of U6 snRNA was quantified by using a TaqMan MicroRNA Assay (Applied Biosystems, Japan). The RNA (10 ng) was used for reverse transcription (RT, 15 l reaction solution) with a Taqman MicroRNA Reverse Transcription kit (Applied Biosystems, Japan). After RT, qPCR was performed using 0.75 l of the RT solution with Taqman Universal Master mix II (Applied Biosystems, Japan, 10 l reaction solution). The expression level of pre-miR145 relative to that of U6 snRNA was quantified by qPCR, using pre-miR145-specific primers (Supplementary Table S1 ). For RT (10 l reaction solution), 10 ng RNA was incubated with Primescript RT kit (Perfect Real Time (Takara, Japan) reagents. After RT, qPCR was performed using 1 l of RT solution and SYBR Premix Ex Taq II (Takara, Japan, 20 l reaction solution).
In vitro decay of tRNAs
The tRNA His transcript (1 g) was dephosphorylated by bacterial alkaline phosphatase (BAP; Takara, Japan), and was 5 -32 P-labeled by T4 polynucleotide kinase (PNK; Toyobo, Japan) and ␥ -[
32 P]-ATP (3000 Ci/mmol, PerkinElmer, Japan). The 5 -32 P labeled tRNA His (5 p-tRNA His ) was methylated by recombinant BCDIN3D, resulting in the synthesis of 5 mp-RNA His . The 5 p-tRNA His and 5 mptRNA His were further purified by acrylamide gel electrophoresis under denaturing conditions. The cytoplasmic fraction of HEK293T cells was prepared with NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, Japan), according to the manufacturer's protocol, and the concentration of proteins in the extracts was quantified by a Bradford assay (Bio-Rad, Japan), using BSA as the standard. The reaction mixtures (90 l), containing 20 mM Tris-Cl, pH 8.0, 100 mM KCl, 3.2 mM MgCl 2 , 1mM DTT, 140 g cytoplasmic protein and 10 000 cpm 5 -ptRNA His (or 5 -mptRNA His ), were incubated at 37
• C. At the indicated times (0, 10, 20, 30, 60, 90, 120 and 150 min), an aliquot (10 l) was withdrawn from the solution, and the RNA was purified by phenol-extraction and ethanol-precipitated. The RNAs were separated by 10% (w/v) polyacrylamide gel electrophoresis under denaturing conditions. The intensities of the intact RNA were quantified with a BASS2000 imager (Fujifilm, Japan).
RESULTS
Cytoplasmic tRNA
His associates with BCDIN3D in vivo
To identify RNA species that interact with BCDIN3D, a HEK293T cell line stably expressing streptavidin binding protein (SBP)-tagged BCDIN3D (SBP-BCDIN3D) was established. The SBP-BCDIN3D in the cell extracts was bound to streptavidin beads, and SBP-BCDIN3D was eluted from the beads by biotin ( Figure 1A) . The electrophoretic analysis of the RNA species that co-purified with SBP-BCDIN3D revealed a distinct RNA with a 70-80 nucleotide length (named RNA-x) that co-purified with SBP-BCDIN3D, but not with the control SBP ( Figure 1B ). This suggested that RNA-x specifically binds to BCDIN3D or BCDIN3D-associating proteins. Over thirty years ago, human and fruit fly cytoplasmic histidyl tRNAs (tRNA His s) were reported to have a 5 -monomethylmonophosphate (23, 24) , and BCDIN3D is localized in the cytoplasm in human cells (9) . Thus, we presumed that RNA-x is a cytoplasmic tRNA His . RT-PCR of the RNA fractions that co-purified with BCDIN3D, using primers specific to cytoplasmic tRNA His , indicated that the cytoplasmic tRNA His co-purified with BCDIN3D, but not with the control SBP from the cell extracts (Figure 1C) . DNA sequencing of the RT-PCR product, amplified using tRNA His -specific primers, confirmed that cytoplasmic tRNA
His indeed co-purified with BCDIN3D. In contrast, cytoplasmic tRNA Phe did not co-purify with BCDIN3D. RT-PCRs also confirmed that neither tRNA His nor tRNA
Phe was co-purified with SBP. Thus, RNA-x was identified as cytoplasmic tRNA His . To substantiate the results, RNA-x was digested with RNase T 1 and subjected to capillary LC-nano ESI-MS analysis (16, 25) . The series of RNA fragments were definitively assigned to the entire sequence of cytoplasmic tRNA His with post-transcriptional modifications (23) (Figure 1D, Supplementary Figure S1A-C) . To detect the 5 terminal fragment of tRNA His , RNA-x was digested with RNase A. An RNA fragment with a molecular mass corresponding to the 5 -terminal trimer with monomethylation, 5 -mpGGCp (mp: monomethylmonophosphate; m/z 1,106), of cytoplasmic tRNA His was identified ( Figure 1D , E, Supplementary Figure S1D) . No RNA fragment with a molecular mass corresponding to either the unmethylated fragment (5 -pGGCp, m/z 1092) or the dimethylated fragment (5 -m 2 pGGCp; m/z 1120) was detected. Collision-induced dissociation (CID) spectrometric analysis of the fragment confirmed the presence of a methylgroup at the 5 -terminal monophosphate of cytoplasmic tRNA His ( Figure 1F ), as previously reported (23) . Together, our results showed that cytoplasmic tRNA His binds to BCDIN3D or its associated proteins, and has a 5 -monomethylmonophosphate. These results prompted us to analyze cytoplasmic tRNA His as a substrate of BCDIN3D.
BCDIN3D monomethylates the 5 -phosphate of tRNA His in vitro
To examine whether BCDIN3D can methylate the 5 -monophosphate of cytoplasmic tRNA His in vitro, BCDIN3D was overexpressed in E. coli, purified and tested for its activity, using a cytoplasmic tRNA His ure S2A and B). This excludes the possibility that the observed methylation of tRNA His by BCDIN3D is due to contamination by other methyltransferases in E. coli. Recently, BCDIN3D was reported to dimethylate the 5 -monophosphates of a specific group of miRNA precursors (pre-miRNAs), such as pre-miR145. The dimethylation of the 5 -phosphate of pre-miR145 negatively regulates the following Dicer processing (9) . However, the methyl group of AdoMet is not significantly transferred to pre-miR145, as compared with tRNA His , under the tested conditions (Figure 2A ).
Under conditions with larger amounts of recombinant BCDIN3D and a prolonged incubation time, a slight amount of the methyl group is transferred to pre-miR145, as detected with a phosphorimager, but the efficiency is much lower than that of tRNA His (∼1%, Figure 2B ). LCmass spectrometric analyses of RNaseA-treated reaction products confirmed that the 5 -monophosphate of tRNA His is fully monomethylated, and the 5 -monophosphate of the pre-miRNA transcript is monomethylated with lower efficiency. Neither tRNA His nor pre-miR145 was dimethylated in vitro ( Figure 2C and D) .
The steady-state kinetics analyses of the methylation of the 5 -monophosphates of tRNA His and pre-miR145 provided estimated K m values for tRNA His and pre-miR145 of 0.25 M and >>15 M, respectively ( Figure 2E) , and the V max value of pre-miR145 was much lower than that of tRNA His . Therefore, cytoplasmic tRNA His is a much better substrate of BCDIN3D than pre-miR145, by over two to three orders of magnitude, in vitro. Thus, the primary target of BCDIN3D is cytoplasmic tRNA His , rather than premiRNAs, and BCDIN3D has monomethylation activity acting on the 5 -monophosphate of cytoplasmic tRNA His . Figure S3) . Quantification of the methylation of the 5 -monophosphate of cytoplasmic tRNA His confirmed that 99% of the cytoplasmic tRNA His has the 5 -monomethylmonophosphate. This suggests that, under normal physiological conditions, the 5 -monophsphate of cytoplasmic tRNA
His is almost fully monomethylated. Next, to examine the monomethylation of the 5 -monophosphate of tRNA His by BCDIN3D in vivo, the BCDIN3D gene in the HEK293T genome was knocked out, using the clustered regulatory interspaced short palindromic repeat CRISPR/Cas9 system (19, 26) . Two knockout cell lines were obtained (KO1 and KO2). Both KO cell lines have nucleotide deletions in exon-1 of the BCDIN3D gene, which lead to the frame-shift mutation of the BCDIN3D mRNA ( Figure 3A) . The absence of BCDIN3D protein expression in the knockout cells was confirmed by western blotting ( Figure 3B ). The knockout of BCDIN3D slightly impairs the growth of HEK293T cells (Supplementary Figure S4A ).
Small RNA fractions were prepared from wild-type HEK293T, KO1 and KO2 cells ( Figure 3C, left) , and subjected to in vitro methylation by recombinant BCDIN3D. While the RNA fractions from HEK293T cells were not significantly methylated, those from the KO1 and KO2 cells were methylated ( Figure 3C, right) . The length of the 14 C-labeled RNA corresponds to that of tRNAs, and no other RNA smaller or larger than the tRNA fractions was 14 C-labeled. The cytoplasmic tRNA His was further purified from the total tRNA fractions of wild-type HEK293T and KO cells, and subjected to in vitro methylation using recombinant BCDIN3D ( Figure 3D ). The tRNA His purified from HEK293T cells was barely methylated by BCDIN3D in vitro, confirming that most of the cytoplasmic tRNA His fraction from the cells bears the 5 -monomethylmonophosphate in vivo ( Supplementary Figure S3) . In contrast, the cytoplasmic tRNA His species purified from the KO cells are methylated in vitro. These results suggest that BCDIN3D is responsible for the methylation of tRNA His in vivo. Analyses by qPCR also confirmed that the expression levels of the 7SK-specific methyltransferase, BCDIN3, in BCDIN3D-knockout cells are not affected (Supplementary Figure S4B) . This excludes the possibility that BCDIN3 is involved in the methylation of tRNA His in vivo.
The tRNA His species from rescued KO cells, in which BCDIN3D was exogenously expressed, are also methylated, but the efficiencies are about half of those of tRNA His from KO cells. This suggests that BCDIN3D methylates cytoplasmic tRNA His in vivo. The exogenous expression levels of SBP-BCDIN3D in KO1 and KO2 were much higher than the endogenous expression of BCDIN3D in wild-type HEK293T cells (Supplementary Figure S5) . Thus, the modest effect (∼ 50%) of the exogenous expression of BCDIN3D in KO cells on the methylation is probably due to the transfection efficiencies of the BCDIN3D plasmid in the KO cells. The cytoplasmic tRNA His species isolated from these cells were further analyzed by LC-mass spectrometry ( Figure 3E,  F) . The results confirmed that, in KO cells, the cytoplasmic tRNA
His lacks the 5 -monomethylmonophosphate, and only the 5 -monophosphate form of tRNA His is observed. Furthermore, in the rescued KO cells, tRNA His with the 5 -monomethylmonophosphate is restored. Thus, BCDIN3D is responsible for the monomethylation of the 5 -monophosphate of cytoplasmic tRNA His in vivo.
Recognition of cytoplasmic tRNA His by BCDIN3D
Human cytoplasmic tRNA His has unique features, among cytoplasmic tRNA species. After the 5 -leader is removed from the precursor tRNA His transcript by an endonuclease, an extra guanosine residue (G −1 ) is attached to the 5 -end by tRNA His guanyltransferase (Thg) (27) . As a result, the mature cytoplasmic tRNA
His has an eight-nucleotide acceptor helix with a protruding C 74 C 75 A 76 sequence, but G −1 does not base-pair with the A 73 discriminator nucleotide (Figure 1D) . In contrast, all other canonical cytoplasmic tRNA species have a seven-nucleotide acceptor helix.
To evaluate the substrate requirement for the methylation of cytoplasmic tRNA His by BCDIN3D, mutation(s) or deletion was introduced into the tRNA His transcript (Figure 4A-D) , and the steady-state kinetics were analyzed. Figure 4C, D) . In addition, the V max value is almost the same as that of tRNA His . Moreover, the tRNA His mini-helix is also methylated efficiently. Thus, the top half of tRNA His , especially the acceptor helix, is recognized by BCDIN3D ( Figure 4E ). The nucleotide preference at position -1 of the tRNA His mini-helix by BCDIN3D was also analyzed, using tRNA His mini-helix variants ( Figure 4F Figure S6A) . In addition, the expression of BCDIN3D in HEK293T cells does not downregulate the expression of mature miR145 ( Supplementary Figure S6B ). These observations are distinct from those in a recent report showing that, in MCF-7 breast cancer cells, the knock-down of BCDIN3D by siRNA results in the upregulation of mature miR145 and the downregulation of pre-miR145 (9) . The expression level of the BCDIN3D protein in HEK293T cells is higher than that in MCF-7 breast cancer cells (Supplementary Figure S7A) . Since almost all of the cytoplasmic tRNA His is methylated even in MCF-7 cells, as in HEK293T and HeLa cells (Supplementary Figure S7B ), the enzymatic activity and amount of BCDIN3D in MCF-7 cells are sufficient to methylate the 5 -phosphate of cytoplasmic tRNA His . These observations suggest the absence of a direct co-relation between the expression levels of the BCDIN3D protein and miR145. Our in vitro results confirmed that BCDIN3D never dimethylates the 5 -monophosphate of either tRNA His or premiR145 ( Figure 2) . A recent report showed that synthetic pre-miR145 with a 5 -dimethylphosphate is poorly processed by Dicer in vitro, while synthetic pre-miR145 with a 5 -monomethylphosphate is processed by Dicer as efficiently as pre-miR145 with a 5 -phosphate (9) . Thus, it is unlikely that miR145 expression is controlled by BCDIN3D, and the 5 -phosphate of pre-miR145 would not be dimethylated by BCDIN3D in HEK293T cells.
cells (Supplementary
Collectively, the primary target of BCDIN3D is cytoplasmic tRNA His , rather than pre-miRNAs, and BCDIN3D has monomethylation activity acting on the 5 -monophosphate of RNAs. Under specific conditions or in certain biological processes, the pre-miRNA might be methylated efficiently, and unknown regulatory factors specific to breast cancer cells might enhance the efficient pre-miRNA (di)methylation process in vivo. The in vivo mechanism of 5 -monophosphate dimethylation of specific pre-miRNAs, such as pre-miR145, in breast cancer cells awaits further studies.
The monomethylation of the 5 -monophosphate of cytoplasmic tRNA His increases both the K m value of tRNA
